Anti-thrombotic, anti-platelet and fibrinolytic therapy: Current management of acute myocardial infarction

Heart Lung and Circulation

Volumn 10, Issue 2, 2001, Pages 68-74

  Helft, Gérard ^a   Worthley, Stephen G ^b  

^a Hùpital Necker   (France)

^b MONASH MEDICAL CENTRE   (Australia)

Author keywords

Anti thrombotic therapy; Myocardial infarction; Thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; ENOXAPARIN; EPTAFIBATIDE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; HIRULOG; LAMIFIBAN; LANOTEPLASE; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARINE; PLACEBO; RETEPLASE; STREPTOKINASE; TENECTEPLASE; THROMBIN INHIBITOR; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DRUG MECHANISM; FIBRINOLYTIC THERAPY; HEART VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; THROMBOCYTE AGGREGATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0035158206     PISSN: 14439506     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1444-2892.2001.00086.x     Document Type: Article

References (47)

1. The pathogenesis of coronary artery disease and the acute coronary syndromes (1)
2. The pathogenesis of coronary artery disease and the acute coronary syndromes (2)
3. Coronary plaque disruption
4. The effects of tissue plasminogen activator, streptokinase, or both on coronary patency, ventricular function, and survival after acute myocardial infarction
5. Hypercoagulable state and thrombolytic drugs
6. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion
7. Platelets and thrombolytic therapy
8. Paradoxical elevation of fibrinopeptide A after streptokinase: Evidence for continued thrombosis despite intense fibrinolysis
9. Thrombin/antithrombin complex level as early predictor of reocclusion after successful thrombolysis
10. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor
11. Effects of plasmin on rabbit platelets
12. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction
13. Human antistreptokinase antibodies induce platelet aggregation in a Fc receptor (CD32) manner
14. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase
15. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy
16. A faster-acting and more potent form of tissue plasminogen activator
17. Randomised, double-blind comparison of reteplase with alteplase for acute myocardial infarction
18. Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction
19. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction
20. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction
21. Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction
22. Immediate coronary angioplasty versus intravenous streptokinase in acute myocardial infarction: Left ventricular ejection fraction, hospital mortality and reinfarction
23. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction
24. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: A quantitative view
25. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction
26. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction
27. Platelet GP IIb-IIIa blockers
28. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation
29. Antiplatelet antibody (7E3 F (ab′) 2) prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model
30. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody
31. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: Results of a randomized, placebo-controlled, dose ranging trial
32. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the Platelet Aggregation Receptor Antagonist Dose Investigation and reperfusion Gain in Myocardial Infarction (PARADIGM) trial
33. IIb/IIIa receptor blockade in acute myocardial infarction
34. Abciximab facilitates the rate and extent of thrombolysis. Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial
35. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction
36. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes
37. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety
38. The ESSENCE trial: Efficacy and safety of subcutaneous enoxaparin in unstable angina and non-Q-wave MI: A double blind, randomized parallel group multicenter study comparing enoxaparin and intravenous and design
39. Management of acute coronary syndromes with low molecular weight heparin: TIMI-11A and 11B
40. Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction: The FATIMA Study
41. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial
42. Initial experience with hirudin and streptokinase in acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial
43. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin inhibition In Myocardial Infarction (TIMI) 9 A trial
44. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
45. Randomized double blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO): Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigation
46. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction
47. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: Myocardial infarction with novastan and TPA (MINT) study